Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
John W OstrominskiMuthiah VaduganathanBrian L ClaggettRudolf A de BoerAkshay S DesaiDan DobreanuAdrian F HernandezSilvio E InzucchiPardeep S JhundMikhail KosiborodCarolyn S P LamAnna M LangkildeDaniel LindholmFelipe A MartinezEileen O'MearaMagnus PeterssonSanjiv J ShahJorge ThiererJohn Joseph Valentine McMurrayScott D SolomonPublished in: European journal of heart failure (2022)
Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time.